Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies

Dr. Paul H. Pevsner, NYU School of Medicine (Department of Pharmacology) and principle investigator for the research studies, commented: "PCT is critical to our work. This novel, cutting-edge technology consistently gives us rapid and reliable extraction of proteins from our important samples. In addition -- and this is very exciting -- PCT has given us the additional extraordinary benefits of not only greater protein yield, but the extraction of proteins not previously identified in these types of samples. Consequently, we believe that the use of PCT, more than the use of any extraction technology available today, could lead to the discovery of new biomarkers for cancer and stroke, which in turn could lead to the development of new diagnostics and therapeutics to combat these diseases."

Dr. Pevsner continued: "Many IVF live births result in twins, triplets, and higher order births. Unfortunately, fetuses and mothers of multiple and high-order multiple pregnancies have increased morbidity and mortality. To combat this, more single embryo transfers are needed. To this end, we have been interested in identifying biomarkers for embryo viability and competence. Using PCT and ProteoSolve-LRS, we identified two proteins in IVF growth media only seen in competent embryos. These proteins may prove to be biomarkers that can enhance selection and result in more live births from single embryo transfers. These are very exciting results."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of PCT to extract new proteins; the speed of sample preparation using PCT compared with other sample preparation methods; the importance of ProteoSolve-LRS and PCT in the reported identification of new proteins in cancer, stroke, and IVF samples; and the possibility that extraction of proteins by ProteoSolve-LRS and PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced selection for single embryo transfers. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of PCT; the possibility that due to the nature of the research being performed, other laboratories may not find the use of ProteoSolve-LRS and PCT to be as advantageous as reported by Dr. Pevsner and his colleagues; due to scientific and medical challenges, the possibility that the data generated by Dr. Pevsner and his colleagues, or that may be generated by other researchers in the future, may not be beneficial in the development of new therapeutics and diagnostics for breast and colon cancer and stroke, and may not result in more live births from single embryo transfers; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    Visit us at our website http://www.pressurebiosciences.com.

    Investor Contacts:
    Richard T. Schumacher, President & CEO          Pressure BioSciences, Inc.
    Edward H. Myles, Senior Vice President          (508) 230-1828 (T)
     of Finance & CFO

SOURCE Pressure BioSciences, Inc.

Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze, Daily News

Tags: ,MTC,HEA,BIO,TRI,SVY,MA-PressureBioReslts

   _   _

           

Is your favorite bookmark site missing? Ask for it.